Accessibility Menu
Entia Biosciences Stock Quote

Entia Biosciences (OTC: ERGO)

$0.00
(0.0%)
+0.00
Price as of January 27, 2026, 2:16 p.m. ET

KEY DATA POINTS

Current Price
$0.00
Daily Change
N/A
Day's Range
$0.00 - $0.00
Previous Close
$0.00
Open
$0.00
Beta
-9.40
Volume
5,575
Average Volume
479
Market Cap
$10K
Market Cap / Employee
$0.00M
52wk Range
$0.00 - $0.04
Revenue
N/A
Gross Margin
N/A
Dividend Yield
N/A
EPS
N/A
CAPs Rating
N/A
Industry
Personal Products

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Entia Biosciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ERGO+200%-98.24%-55.4%-100%
S&P+15.58%+78.13%+12.24%+426%

Entia Biosciences Company Info

Entia Biosciences, Inc. operates as a biotechnology company. It is engaged in the discovery, formulation, production and marketing of functional ingredients that can be used in branded medical foods, nutraceuticals, cosmetics and other products. The firm markets nutraceutical products under the GROH and SANO brands direct to consumers online and through hair salons and other resellers in North America. The company was founded by Marvin S. Hausman on July 19, 2007 and is headquartered in Sherwood, OR.

News & Analysis

No results found

No news articles found for Entia Biosciences.

Financial Health

General

No data available

No data available for this period.

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

No data available

No data available for this period.

Liabilities

No data available

No data available for this period.

Ratios

No data available

No data available for this period.

Cash Flow

No data available

No data available for this period.

Valuation

MetricYoY Change

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.